home / stock / lxrp / lxrp news

LXRP News and Press, Lexaria Bioscience Corp.

Stock Information
Company Name: Lexaria Bioscience Corp.
Stock Symbol: LXRP
Market: OTC
Website: lexariabioscience.com
Menu
LXRP LXRP Quote LXRP Short LXRP News LXRP Articles LXRP Message Board
Get LXRP Alerts

News, Short Squeeze, Breakout and More Instantly...
LXRP - Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, pleas...
LXRP - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“I...

LXRP - Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” ...

LXRP - Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IB...
LXRP - Lexaria Bioscience CEO: Faster, Cost-efficient Drug Delivery Platform for COVID-19 and Beyond

Lexaria Bioscience (NASDAQ:LEXX,CSE:LXX) concluded its expanded research program for DehydraTECH-enabled remdesivir and ebastine, showing effective results in inhibiting the COVID-19 SARS-CoV-2 virus . Lexaria Bioscience CEO Chris Bunka discussed the technology ’s poten...

LXRP - Lexaria's Antiviral Drug Evaluation Program Progressing

(TheNewswire) - Two of the four planned studies progressing to examine DehydraTECH™ with antivirals targeting SARS-CoV-2 / COVID-19 Kelowna, British Columbia - TheNewswire - March 16, 2021 – Lexaria Bioscien...

LXRP - Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

(TheNewswire) - Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies Kelowna, British Columbia – TheNewswir...
LXRP - Lexaria Enters Investor Relations Agreement

(TheNewswire) Kelowna, British Columbia – TheNewswire - February 16, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”),...

LXRP - Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies

(TheNewswire) - Hypertension program evaluating effectiveness of DehydraTECH-processed CBD now consists of three human clinical studies and two animal studies Kelowna, British Columbia – TheNewswire - February 11, 2021...

LXRP - Lexaria Provides Guidance on Upcoming R&D

(TheNewswire) Kelowna, British Columbia - TheNewswire - February 1, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (C NSX :LXX. CN ) (the “Company” or “Lexaria”), a global ...
Next 10